Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040656 | 0.90 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL8053441 | 0.90 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL213640 | 0.88 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL8713034 | 0.87 | CDK1 (0.41) | PTGS2CDK1CDK2KDRPTGS1 | |
| SCHEMBL8040705 | 0.86 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL8051557 | 0.85 | ALOX5 (0.39) | PTGS2CDK1CDK2KDR | |
| SCHEMBL8040663 | 0.85 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL215649 | 0.84 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL8051576 | 0.82 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL8302968 | 0.81 | PTGS2 (0.50) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-1479385-A1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. Searle LLC (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | SEIBERT KAREN (US) | 2004-09-23 | — | — | US | claimed |
| EP-0932402-B1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | SEARLE LLC (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | claimed |
| EP-1435956-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | Pharmacia Corporation (US) | 2004-07-14 | — | — | EP | claimed |
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. SEARLE & CO. | 2001-11-29 | — | — | US | claimed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| EP-0808305-B1 | 3,4-DIARYL SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885CDK1 598/4885CDK2 122/4885 |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | APP, BACE2, PTGS2 | PTGS2 3/4885CDK1 4250/4885CDK2 2861/4885 |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | HMGCR, HMGB2, HMGB3 | PTGS2 7/4885CDK1 3423/4885CDK2 2369/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885CDK1 2011/4885CDK2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.